The efficacy and safety of golimumab in the treatment of arthritis

Bibliography

• Helmick C, Felson D, Lawrence R, Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 2008;58:15-25
   PubMed Web of Science ®Google Scholar
• MacGregor AJ, Silman AJ. Classification and epidemiology. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors, Rheumatology. 3rd edition. Elsevier Science, Phildelphia PA, USA; 2003. p. 757-763
   Google Scholar
• Albers JM, Kuper HH, Van Riel PL, Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 1999;38:423-30
   PubMed Web of Science ®Google Scholar
• Habib G, Artul S, Ratson N, Froom P. Household work disability of Arab housewives with rheumatoid arthritis. Clin Rheumatol 2007;26:759-63
   PubMed Web of Science ®Google Scholar
• Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum 2009;38:320-35
   PubMed Web of Science ®Google Scholar
• Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol 2009;36:1012-20
   PubMed Web of Science ®Google Scholar
• Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 2009;26:1681-5
   Google Scholar
• van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Effects of rheumatoid arthritis on employment and social participation during the first years of disease in The Netherlands. Br J Rheumatol 1998;37:848-53
   PubMedGoogle Scholar
• Wallenius M, Skomsvoll JF, Koldingsnes W, Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 2009;68:685-9
   PubMed Web of Science ®Google Scholar
• Young A, Dixey J, Cox N, How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives?. Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000;39:603-11
   PubMed Web of Science ®Google Scholar
• Young A, Dixey J, Kulinskaya E, Which patients stop working because of rheumatoid arthritis?. Results of five years' follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002;61:335-40
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Barton M, Greenberg PE, Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000;42:588-96
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004;31:849-55
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008;8:S49-S60
   PubMed Web of Science ®Google Scholar
• Olivieri I, Mantovani LG, D'Angelo S, Psoriatic arthritis: pharmacoeconomic considerations. Curr Rheumatol Rep 2009;11:263-9
   PubMedGoogle Scholar
• Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol: 2005;32:1875-83
   PubMed Web of Science ®Google Scholar
• Dunlop DD, Manheim LM, Yelin EH, The costs of arthritis. Arthitis Rheum 2003;49:101-13
   PubMed Web of Science ®Google Scholar
• Aletaha D, Eberl G, Nell VP, Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2004;63:1269-75
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X. Treatment of ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2009;21:324-34
   PubMed Web of Science ®Google Scholar
• Breedveld FC. Should rheumatoid arthritis be treated conservatively or aggressively? Rheumatology (Oxford) 2003;42(Suppl 2):ii41-ii43
   PubMedGoogle Scholar
• Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9
   PubMed Web of Science ®Google Scholar
• Mease PJ. Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol 2009;21:348-55
   PubMed Web of Science ®Google Scholar
• Olivieri I, D'Angelo S, Palazzi C, Padula A. Treatment strategies for early psoriatic arthritis. Expert Opin Pharmacother 2009;10:271-82
   PubMed Web of Science ®Google Scholar
• Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003;21:S209-S21
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kalden JR, Scott DL, Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259-66
   PubMed Web of Science ®Google Scholar
• Strand V, Cohen S, Schiff M, Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Coblyn JS, Fox DA, Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Polisson R, Blotner SD, The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613-9
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M, Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van VR, Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2008;68:805-11
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 2004;31:1103-11
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
   PubMed Web of Science ®Google Scholar
• Cohen S, Hurd E, Cush J, Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewe RB, Mease P, Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, A trial of etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde DM, de Jager JP, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS, Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43
   PubMed Web of Science ®Google Scholar
• Westhovens R, Robles M, Ximenes AC, Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7
   PubMed Web of Science ®Google Scholar
• Van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol 1996;35(Suppl 2):4-7
   PubMedGoogle Scholar
• Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, Van Riel PL, Nuver-Zwart IH, Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, van der Heijde D, Braun J, Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH, Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Salonen D, Weissman BN, Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Brandt J, Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007;46:1450-3
   PubMed Web of Science ®Google Scholar
• Braun J, Deodhar A, Dijkmans B, Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008;59:1270-8
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, van der Heijde D, Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-76
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni C, Mease P, Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006;33:2254-9
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni CE, Gladman D, The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-43
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni C, Krueger GG, Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006;65:471-7
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kavanaugh A, Gladman DD, Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007;56:2698-707
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Cifaldi MA, Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007;66:163-8
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT, Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23
   PubMed Web of Science ®Google Scholar
• Hyrich K, Lunt M, Watson K, Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthitis Rheum 2007;56:13-20
   PubMed Web of Science ®Google Scholar
• Schiff M, Pritchard C, Huffstutter JE, The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68:1708-14
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8
   PubMed Web of Science ®Google Scholar
• Golimumab Product Information. Centocor, Malvern PA; 2009
   Google Scholar
• Zhou H, Jang H, Fleischmann RM, Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-96
   PubMed Web of Science ®Google Scholar
• Adalimumab Product Information. Abbott, Abbott Park, IL; 2010
   Google Scholar
• Emery P, Fleischmann RM, Moreland LW, Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272-83
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, van der Heijde D, Golimumab and radiographic progression in rheumatoid arthritis: results of GO-BEFORE and GO-FORWARD Studies [abstract 640] Arthitis Rheum 2009;60
   Google Scholar
• Felson DT, Anderson JJ, Boers M, The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Klareskog L, Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21
   PubMed Web of Science ®Google Scholar
• Van der Linden S, Valkenburg H, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthitis Rheum 1984;27:361-8
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy L, A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC Jr, van der Heijde D, Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, Phase III trial. Arthritis Rheum 2008;58:3402-12
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Baron G, van der Heijde DM, Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthitis Rheum 2001;44:1876-86
   PubMed Web of Science ®Google Scholar
• Calin A, Garrett S, Whitelock H, A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5
   PubMed Web of Science ®Google Scholar
• Jenkinson T, Mallorie P, Whitelock H. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994;21:1694-8
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978;157:238-44
   PubMedGoogle Scholar
• Rich P, Scher RK. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12
   PubMed Web of Science ®Google Scholar
• Kremer J, Ritchlin C, Mendelsohn A, Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-28
   PubMed Web of Science ®Google Scholar
• Genovese MC, Keystone E, Hsia EC, Golimumab significantly improves physical function, health-related quality of life, and fatigue in RA patients: results from the GO-FORWARD Study [abstract 1040]. Arthitis Rheum 2008;58
   Google Scholar
• Kay J, Matteson EL, Dasgupta B, Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75
   PubMed Web of Science ®Google Scholar
• Fleischmann R. Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? Rheum Dis Clin North Am 2006, 1:2-9
   Google Scholar